NBIX - Neurocrine Biosciences, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
IPO Date: May 23, 1996
Sector: Healthcare
Industry: Biotech
Market Cap: $14.58B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.02 | 2.17%
Avg Daily Range (30 D): $2.21 | 1.47%
Avg Daily Range (90 D): $2.89 | 1.77%
Institutional Daily Volume
Avg Daily Volume: .7M
Avg Daily Volume (30 D): .93M
Avg Daily Volume (90 D): .98M
Trade Size
Avg Trade Size (Sh.): 88
Avg Trade Size (Sh.) (30 D): 40
Avg Trade Size (Sh.) (90 D): 43
Institutional Trades
Total Institutional Trades: 12,750
Avg Institutional Trade: $4.29M
Avg Institutional Trade (30 D): $13.87M
Avg Institutional Trade (90 D): $11.81M
Avg Institutional Trade Volume: .05M
Avg Institutional Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $10.48M
Avg Closing Trade (30 D): $39.42M
Avg Closing Trade (90 D): $37.38M
Avg Closing Volume: 105.11K
 
News
Aug 26, 2026 @ 7:33 AM
Nxera Pharma’s Partner Neurocrine Bioscienc...
Source: Nxera Pharma
Aug 7, 2026 @ 6:30 AM
Nxera Pharma Operational Highlights and Consolidat...
Source: Nxera Pharma
Jun 10, 2026 @ 8:44 PM
Tom Lee's Small-Cap Granny Shots ETF Reloads: Firs...
Source: Chandrima Sanyal
May 1, 2026 @ 6:36 AM
Nxera Pharma Operational Highlights and Consolidat...
Source: Nxera Pharma
Apr 12, 2026 @ 11:30 PM
Nxera Pharma’s Partner Neurocrine Bioscienc...
Source: Na
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $7.05 $1.43 $1.97
Diluted EPS $6.82 $1.39 $1.91
Revenue $3.37B $959M $814.5M
Gross Profit $800.7M
Net Income / Loss $705.5M $144.4M $197.9M
Operating Income / Loss $794.8M $151.5M $193.4M
Cost of Revenue $13.8M
Net Cash Flow $66.9M $64.4M $-446.5M
PE Ratio